Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial

作者：Jinjing Liu, Ying Jiang, Shangzhu Zhang, Shengyun Liu, Jingbo Su, Changsong Lin, Xiaohong He, Rui Wu, Lei Yang, Huaxiang Liu, Xinwang Duan, Shengqian Xu, Hui Luo, Jing Liu, Qibing Xie, Cundong Mi, Lin Chen, Ning Zhang, Huiping Gong, Jing Zhu, Yasong Li, Wei Hua, Long Qian, Jian Wang, Xiaofei Shi, Hongtao Jin, Zhenyu Jiang, Xi Xie, Feng Zhan, Xiuqin Geng, Zhaohui Zheng, Zhenggui Du, Guangchao Dong, Yuqi Sun, Xiaofeng Zeng · 发表于：Annals of the Rheumatic Diseases · 年份：2025 · DOI：10.1136/ard-2024-226385 · 被引用次数：21 · 研究领域：Rheumatoid Arthritis Research and Therapies、Cytokine Signaling Pathways and Interactions、Spondyloarthritis Studies and Treatments